Biomarkers and Surrogates in Clinical Studies
Biomarkers are defined as anatomic, physiologic, biochemical, molecular, or genetic parameters associated with the presence, absence, or severity of a disease process. As such, biomarkers may be useful as prognostic and diagnostic tests. Establishing the utility of a given biomarker as a prognostic or diagnostic test requires the conduct of carefully designed cohort studies in which the biomarker and the outcome of interest are measured independently. The design and analysis of such studies is discussed.
Surrogate outcomes in clinical trials consist of events or biomarkers intended to reflect important clinical outcomes. Surrogate outcomes may offer advantages in providing statistically robust estimates of treatment effects with smaller sample sizes. However, to be useful, surrogate outcomes have to be validated to ensure that the effect of therapy on them truly reflects the effect of therapy on the important clinical outcomes of interest.
KeywordsBiomarkers risk factors prognosis diagnosis intervention studies surrogate outcomes validation studies
- 3.3. Wang, T. J., Gona, P., Larson, M. G., Tofler, G. H., Levy, D., Newton-Cheh, C., Jacques, P. F., Rifai, N., Selhub, J., Robins, S. J., Benjamin, E. J., D'Agostino, R. B., Vasan, R. S. (2006). Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355, 2631–2639.PubMedCrossRefGoogle Scholar
- 4.4. Sackett, D., Haynes, R., Guyatt, G., Tugwell, P. (1991). The interpretation of diagnostic data, in Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd ed. Little, Brown and Company, Toronto.Google Scholar
- 5.5. Kleinbaum, D. G. (1996). Survival Analysis: A Self-Learning Text. Springer-Verlag, New York.Google Scholar
- 6.6. Cox, D. R., Oakes, D. (1984). Analysis of Survival Data. Chapman and Hall/CRC, Boca Raton, FL.Google Scholar
- 11.11. Nissen, S. E., Tardif, J. C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., Tuzcu, E. M., ILLUSTRATE Investigators. (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356, 1304–1316.PubMedCrossRefGoogle Scholar
- 12.12. LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J. C., Gotto, A. M., Greten, H., Kastelein, J. J., Shepherd, J., Wenger, N. K. (2005) Treating to new targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352, 1425–1435.PubMedCrossRefGoogle Scholar
- 15.15. Gail, M. H., Pfeiffer, R., Houwelingen, H. C., Carroll, R. J. (2001). On meta-analytic assessment of surrogate outcomes. Biostatistics 3, 231–246.Google Scholar